273 related articles for article (PubMed ID: 17195210)
1. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
Hayer S; Redlich K; Korb A; Hermann S; Smolen J; Schett G
Arthritis Rheum; 2007 Jan; 56(1):79-88. PubMed ID: 17195210
[TBL] [Abstract][Full Text] [Related]
2. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
[TBL] [Abstract][Full Text] [Related]
4. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
Patten C; Bush K; Rioja I; Morgan R; Wooley P; Trill J; Life P
Arthritis Rheum; 2004 Oct; 50(10):3334-45. PubMed ID: 15476226
[TBL] [Abstract][Full Text] [Related]
5. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.
van Lent PL; Grevers L; Lubberts E; de Vries TJ; Nabbe KC; Verbeek S; Oppers B; Sloetjes A; Blom AB; van den Berg WB
Arthritis Rheum; 2006 Dec; 54(12):3868-77. PubMed ID: 17133594
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
[TBL] [Abstract][Full Text] [Related]
7. JNK1 is not essential for TNF-mediated joint disease.
Köller M; Hayer S; Redlich K; Ricci R; David JP; Steiner G; Smolen JS; Wagner EF; Schett G
Arthritis Res Ther; 2005; 7(1):R166-73. PubMed ID: 15642137
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo.
Görtz B; Hayer S; Tuerck B; Zwerina J; Smolen JS; Schett G
Arthritis Res Ther; 2005; 7(5):R1140-7. PubMed ID: 16207331
[TBL] [Abstract][Full Text] [Related]
9. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S; Ma JY; Mangadu R; Jiang Y; Zhao JJ; Almirez R; Kerr I; Stebbins EG; O'Young G; Kapoun AM; Luedtke G; Chakravarty S; Dugar S; Genant HK; Protter AA
J Pharmacol Exp Ther; 2006 Jul; 318(1):132-41. PubMed ID: 16597712
[TBL] [Abstract][Full Text] [Related]
10. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis.
Saito H; Kojima T; Takahashi M; Horne WC; Baron R; Amagasa T; Ohya K; Aoki K
Arthritis Rheum; 2007 Apr; 56(4):1164-74. PubMed ID: 17393436
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Schurigt U; Hummel KM; Petrow PK; Gajda M; Stöckigt R; Middel P; Zwerina J; Janik T; Bernhardt R; Schüler S; Scharnweber D; Beckmann F; Saftig P; Kollias G; Schett G; Wiederanders B; Bräuer R
Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
[TBL] [Abstract][Full Text] [Related]
13. Osteoclasts are essential for TNF-alpha-mediated joint destruction.
Redlich K; Hayer S; Ricci R; David JP; Tohidast-Akrad M; Kollias G; Steiner G; Smolen JS; Wagner EF; Schett G
J Clin Invest; 2002 Nov; 110(10):1419-27. PubMed ID: 12438440
[TBL] [Abstract][Full Text] [Related]
14. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
Matsuno H; Yoshida K; Ochiai A; Okamoto M
J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387
[TBL] [Abstract][Full Text] [Related]
15. Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production.
Abdollahi-Roodsaz S; Joosten LA; Helsen MM; Walgreen B; van Lent PL; van den Bersselaar LA; Koenders MI; van den Berg WB
Arthritis Rheum; 2008 Dec; 58(12):3753-64. PubMed ID: 19035506
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
[TBL] [Abstract][Full Text] [Related]
17. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee.
Bolon B; Campagnuolo G; Zhu L; Duryea D; Zack D; Feige U
Vet Pathol; 2004 May; 41(3):235-43. PubMed ID: 15133172
[TBL] [Abstract][Full Text] [Related]
19. Different amplifying mechanisms of interleukin-17 and interferon-gamma in Fcgamma receptor-mediated cartilage destruction in murine immune complex-mediated arthritis.
Grevers LC; van Lent PL; Koenders MI; Walgreen B; Sloetjes AW; Nimmerjahn F; Sjef Verbeek J; van den Berg WB
Arthritis Rheum; 2009 Feb; 60(2):396-407. PubMed ID: 19180490
[TBL] [Abstract][Full Text] [Related]
20. CD44 is a determinant of inflammatory bone loss.
Hayer S; Steiner G; Görtz B; Reiter E; Tohidast-Akrad M; Amling M; Hoffmann O; Redlich K; Zwerina J; Skriner K; Hilberg F; Wagner EF; Smolen JS; Schett G
J Exp Med; 2005 Mar; 201(6):903-14. PubMed ID: 15781582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
